Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,661 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depressive Disorder, Major Depressive Disorder Clear all
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Intern Health Study 2025

NCT07052357
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Mood, Sleep, Physical Activity
Interventions
Intern Health Study behavioral change mobile notification
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jul 23, 2026, 11:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploring Biomarkers for Depression

NCT01424111
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Healthy Control
Drug · Other
Lead sponsor
Wyss Institute at Harvard University
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1Phase 2 Interventional

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

NCT01381107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Jul 23, 2026, 11:40 PM EDT
Recruiting Not applicable Interventional

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

NCT06423430
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Sham-stimulation, Active-stimulation
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
22 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

NCT01500200
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Tucson, Arizona • Oceanside, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jul 23, 2026, 11:40 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

NCT01803711
View directory record Official record
Conditions
Major Depression, Cancer, Diabetes, Cardiovascular Diseases
Interventions
Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement)
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1Phase 2 Interventional

Cognitive Training for Depression

NCT01936506
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Training A, Cognitive Training B
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Jul 23, 2026, 11:40 PM EDT
Terminated Phase 1Phase 2 Interventional

Biomarkers of Response to Treatment With Frontal Cortex Stimulation for Anxious Depression

NCT03999736
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety
Interventions
transcranial direct current stimulation using a Soterix mini-CT device
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 28 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1 Interventional

Continuation Ketamine in Major Depression

NCT00548964
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lithium, Ketamine
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 4 Interventional

Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)

NCT00479726
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2007 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Not applicable Interventional

Transcranial Direct Current Stimulation (tDCS) Therapy in Major Depression

NCT04507243
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active - HD tDCS, Sham - HD tDCS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 23, 2026, 11:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Behavioral Processes Underlying Reward Processing in Depression

NCT00205933
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Affective Neuroscience Laboratory
Other
Eligibility
18 Years to 64 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 2 Interventional Results available

Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)

NCT01625845
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions
Pentoxifylline, Placebo, Standard Treatment
Drug · Other · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1 Interventional

Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients

NCT00541957
View directory record Official record
Conditions
Major Depression
Interventions
behavior therapy, Medication prescribed by PCP
Behavioral · Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Escitalopram in Adult Patients With Major Depressive Disorder

NCT00668525
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
45
States / cities
Phoenix, Arizona • Arcadia, California • Encino, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses

NCT00494650
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Cognitive behavioral therapy (CBT), Brief PTSD treatment
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Monmouth Junction, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 23, 2026, 11:40 PM EDT
Terminated No phase listed Observational

Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features

NCT01310140
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Jul 23, 2026, 11:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Biological Markers for Severe Depression

NCT01831882
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
3
States / cities
Irvine, California • Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

NCT01263197
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, albuterol, propranolol, placebo for LY2216684, placebo for albuterol, placebo for propranolol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Not applicable Interventional

Rise Study for Depression

NCT06003361
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Digital CBT, Waitlist
Device · Other
Lead sponsor
Big Health Inc.
Industry
Eligibility
22 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jul 23, 2026, 11:40 PM EDT
Terminated Phase 3 Interventional

Treatment of Major Depressive Disorder With Psychotic Features.

NCT00174590
View directory record Official record
Conditions
Major Depression With Psychotic Features
Interventions
risperidone
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

NCT00321490
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jul 23, 2026, 11:40 PM EDT